Clinical experience in coronary bypass surgery for abciximab-treated patients

Annals of Thoracic Surgery

Volumn 70, Issue 2 SUPPL., 2000, Pages

  Lemmer Jr , John H ^a,b  

^a Northwest Surgical Associates   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO;

ANTICOAGULATION; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 0033831321     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01605-2     Document Type: Article

References (22)

1. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
2. Reduced need for coronary bypass surgery (CABG) after percutaneous intervention in patients treated with abciximab
3. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab?
4. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
5. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
6. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
7. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
8. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
9. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
10. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
11. Blood use in emergency coronary artery bypass after receipt of abciximab during angioplasty
12. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
13. Emergency coronary artery bypass surgery in abciximab-treated patients
14. Safe use of platelet GP IIb/IIIa inhibitors
15. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
16. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty for directional atherectomy (the EPIC trial)
17. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery
18. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
19. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation
20. Preclinical development of c7E3 Fab: A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
21. Reversal of antiplatelet effect of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys
22. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention